Overview of Dr. Laccetti
I am a medical oncologist specializing in the management of prostate cancer and other malignancies of the genitourinary tract. My primary aim is to provide evidence-based, personalized patient care that balances aggressive treatment strategies and quality of life.
I have a strong foundation in clinical and outcomes research previously investigating strategies to improve access to oncology clinical trials and how cancer patients interface with electronic medical record portals. My current research aims to develop novel remote monitoring strategies for cancer patients utilizing emerging technologies including wearable activity trackers (such as Fitbit®) and smart-phone survey applications. Through development and implementation of these tools, I hope to achieve greater insight into the patient experience facilitating improvement of clinical trial design, patient safety, outcomes and treatment selection. I am also investigating the relationship between prostate cancer, metabolic syndrome and physical activity/exercise. I hope to develop prescriptive exercise interventions to improve prostate cancer outcomes and quality of life, while informing disease biology.
In my free time, I enjoy the running, hiking, ice hockey and spending time with my wife.
Office
Memorial Sloan Kettering Cancer Center Bergen
225 Summit Avenue
New York, NY 10021- Is this information wrong?
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2016 - 2019
University of Texas Southwestern Medical CenterResidency, Internal Medicine, 2012 - 2015
Albany Medical CollegeClass of 2012
Union CollegeB.S., Chemistry - Music, Suma Cum Laude
Certifications & Licensure
NJ State Medical License 2019 - 2025
NY State Medical License 2019 - 2024
TX State Medical License 2014 - 2022- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- A Phase 1, Open-label, Dose-Ascending Study to Evaluate the Safety and Tolerability of the Therapeutic Radiopharmaceutical 131I-MIP-1095 for the Treatment of Metastati...Andrew L Laccetti, Lisa Bodei, Joseph A O'Donoghue, Wolfgang A Weber, Michael J Morris> ;Clinical Nuclear Medicine. 2023 Nov 1
- 51 citationsPhase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates.Chung-Han Lee, Martin H Voss, Maria Isabel Carlo, Ying-Bei Chen, Mark Zucker, Andrea Knezevic, Robert A Lefkowitz, Natalie Shapnik, Chloe Dadoun, Ed Reznik, Neil J Sha...> ;Journal of Clinical Oncology. 2022 Jul 20
- 13 citationsCombination antiangiogenic tyrosine kinase inhibition and anti‐PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and...Andrew Leonard Laccetti, Benjamin Garmezy, Lianchun Xiao, Minas Economides, Aradhana M. Venkatesan, Jianjun Gao, Eric Jonasch, Paul G. Corn, Amado Zurita-Saavedra, Lan...> ;Cancer Medicine. 2021 Mar 1
- Join now to see all
Press Mentions
Men Who Drink Milk at Higher Risk for Prostate CancerJune 11th, 2022- Obesity in Men Linked to Increased Risk of Fatal Prostate CancerMay 6th, 2022
- Obesity Raises a Man's Odds for Fatal Prostate CancerMay 5th, 2022
- Join now to see all
Other Languages
- Spanish
Hospital Affiliations
Memorial Sloan Kettering Cancer CenterNew York, New York- Memorial Sloan Kettering BergenMontvale, New Jersey
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
